FDA Inspection
Boehringer Ingelheim RCV GmbH & Co KGBoehringer Ingelheim RCV GmbH & Co KG – FDA Inspection, Mar 2, 2023
Record Details
This FDA Inspection record concerns Boehringer Ingelheim RCV GmbH & Co KG, with an inspection on March 2, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.
- Person
- MRA McCulloughJ (Issuing Officer)
View Company Profile
ID · 3cfa7c2f-3876-4a03-8a8f-2b34332d7f2c
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 1210971
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of Boehringer Ingelheim RCV GmbH & Co KG
13| Date | Classification | Office | Project area |
|---|---|---|---|
| November 12, 2024 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| December 5, 2023 | Not classified | Office of Inspections and Investigations | |
| November 16, 2023 | Not classified | Office of Inspections and Investigations | |
| September 16, 2022 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| January 28, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Boehringer Ingelheim RCV GmbH & Co KG
- FDA Inspection 1258048 - 2024-11-12
- FDA Inspection 1226783 - 2023-12-05
- FDA Inspection 1223893 - 2023-11-16
- FDA Inspection 1182096 - 2022-09-16
- FDA Inspection 1170761 - 2021-01-28
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.